NCT04090086View on ClinicalTrials.gov

A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

December 10, 2019

Study Completion Date

December 10, 2019

Conditions
Healthy
Interventions
DRUG

JNJ-53718678

JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.

DRUG

JNJ-64417184

JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.

Trial Locations (1)

9728 NZ

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04090086 - A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants | Biotech Hunter | Biotech Hunter